Establish a Priority Nonprescription Drug designation to expedite development and review of certain over-the-counter medications.

Robert E. Latta · Ohio · Republican

policy impact 0.50 specificity 0.85 extraction confidence 84%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

The Nonprescription Drug Innovation Act would establish a new “Priority Nonprescription Drug” designation to help expedite the development and review of certain over-the-counter (OTC) medications to give consumers access to manage their own care in a safe and affordable manner.

Latta promoted the Nonprescription Drug Innovation Act, which would create a new priority designation to speed development and review of certain OTC drugs.

Latta's Bills to Combat Rising Synthetic Opioid Deaths Advanced by House Energy and Commerce Committee
primary · press_release · model gpt-5.5

Evidence

legacy_unverified · Source version not recorded · locator unknown

H.R. 9774 was introduced by Mr. Latta and referred to Energy and Commerce. The bill would create Sec. 506M, allowing FDA to designate priority nonprescription drugs and take actions to facilitate development and expedite review.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official bill text directly matches the commitment, but it is only an introduced bill and referral, not an enacted designation program.

unresolved same_term A for effort

H.R. 9774 Introduced in House - Priority Nonprescription Drugs
secondary · model gpt-5.5 · confidence 96%

Contest this evidence item

legacy_unverified · Source version not recorded · locator unknown

Latta's office said the Committee passed his Nonprescription Drug Innovation Act, H.R. 9774, as part of H.R. 9393, and described it as establishing a Priority Nonprescription Drug designation.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): This indicates additional concrete legislative progress beyond introduction, but the designation still has not been established in law as of the August 20, 2026 refresh.

unresolved same_term A for effort

Latta's Bills to Combat Rising Synthetic Opioid Deaths Advanced by House Energy and Commerce Committee
primary · model gpt-5.5 · confidence 88%

Contest this evidence item

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): never. unknown A for effort

Latta introduced H.R. 9774 and advanced it through committee language in H.R. 9393 during the same federal term, and the bill directly matches the promise by creating a Priority Nonprescription Drug designation for FDA review. But the evidence says the designation had not been established in law as of August 20, 2026. Because this was a serious legislative attempt that did not deliver the promised enacted outcome, it should be scored as never with effort credit.

provider codex_cli · model gpt-5.5 · confidence 91%